The Consumption of Interacting Drugs with Bleeding Risk in Estonia from 2012 to 2019 and Related Bleeding Incidents
Name
Grete Mägi
Abstract
This study investigated the usage of interacting drug pairs with potential bleeding risk and the occurrence of bleeding diagnoses in patients who used these drug combinations. Specifically, it examined which drug pairs were used, how the usage trends of these ingredient pairs changed over time, the number of bleeding diagnoses received, and which ingredient pairs were involved.
The data used in the study were sourced from three databases: the Health Insurance Fund Prescription Center (prescribed and dispensed medications), the claims data repository, and the Health Information System (discharge summaries and referral responses). The dataset included a random sample of 10% of all individuals in Estonia with a national ID number (n=150 824) and their health data from 2012–2019. Medications were purchased by 138,572 persons during
this period.
The results of the study showed that 14,901 patients (10,8% of all patients who purchased medications) used drug pairs associated with a bleeding risk, of which 651 received a bleeding diagnosis (4,4% of patients). Among the 651 patients who experienced bleeding, there were 2847 bleeding episodes. Bleeding was most frequently associated with the use of drug pairs involving warfarin combined with torsemide, omeprazole, and allopurinol. The average age at the time of the first bleeding episode was 72,1 years (SD ±12,5), and the risk of bleeding was higher in men. Age is a significant factor in the occurrence of bleeding, with the majority of
bleeding events occurring in the 60+ age group.
The data used in the study were sourced from three databases: the Health Insurance Fund Prescription Center (prescribed and dispensed medications), the claims data repository, and the Health Information System (discharge summaries and referral responses). The dataset included a random sample of 10% of all individuals in Estonia with a national ID number (n=150 824) and their health data from 2012–2019. Medications were purchased by 138,572 persons during
this period.
The results of the study showed that 14,901 patients (10,8% of all patients who purchased medications) used drug pairs associated with a bleeding risk, of which 651 received a bleeding diagnosis (4,4% of patients). Among the 651 patients who experienced bleeding, there were 2847 bleeding episodes. Bleeding was most frequently associated with the use of drug pairs involving warfarin combined with torsemide, omeprazole, and allopurinol. The average age at the time of the first bleeding episode was 72,1 years (SD ±12,5), and the risk of bleeding was higher in men. Age is a significant factor in the occurrence of bleeding, with the majority of
bleeding events occurring in the 60+ age group.
Graduation Thesis language
Estonian
Graduation Thesis type
Master - Conversion Master in IT
Supervisor(s)
Marek Oja, Sirli Tamm
Defence year
2024